Reports Q2 revenue $34.76M, consensus $32.05M. "The consistent execution by our team has strengthened and expanded our customer base, and significantly improved the company’s financial position as compared to prior years. Our topline revenues remain strong and our backlog continues to show strong growth over the prior year. The investment in our business development team is already showing positive results ahead of the completion of our new capacity and services soon to come online. We fully expect this momentum to continue and for all of these reasons, I am pleased to report that Avid is increasing its revenue guidance for the full fiscal year 2023 to between $145 million and $150 million," stated Nick Green, president and chief executive officer of Avid Bioservices.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CDMO:
- Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2022 and Recent Developments
- Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022
- Avid Bioservices Appoints Oksana Lukash as Vice President, People
- Avid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare Conference